CN111278847B - 分子导向系统肽及其用途 - Google Patents

分子导向系统肽及其用途 Download PDF

Info

Publication number
CN111278847B
CN111278847B CN201880055674.8A CN201880055674A CN111278847B CN 111278847 B CN111278847 B CN 111278847B CN 201880055674 A CN201880055674 A CN 201880055674A CN 111278847 B CN111278847 B CN 111278847B
Authority
CN
China
Prior art keywords
seq
mgs
artificial sequence
ala
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880055674.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN111278847A (zh
Inventor
凯瑟琳·C·布朗
N·柯林斯
李顺子
柯蒂斯·奥尔雷德
基恩·钟
迈克尔·麦圭尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SRI International Inc
Original Assignee
SRI International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SRI International Inc filed Critical SRI International Inc
Priority to CN202410388889.9A priority Critical patent/CN118221770A/zh
Publication of CN111278847A publication Critical patent/CN111278847A/zh
Application granted granted Critical
Publication of CN111278847B publication Critical patent/CN111278847B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/05—Fusion polypeptide containing a localisation/targetting motif containing a GOLGI retention signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
CN201880055674.8A 2017-07-10 2018-07-10 分子导向系统肽及其用途 Active CN111278847B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410388889.9A CN118221770A (zh) 2017-07-10 2018-07-10 分子导向系统肽及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762530633P 2017-07-10 2017-07-10
US62/530,633 2017-07-10
PCT/US2018/041403 WO2019014190A1 (en) 2017-07-10 2018-07-10 MOLECULAR GUIDANCE SYSTEM PEPTIDES AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410388889.9A Division CN118221770A (zh) 2017-07-10 2018-07-10 分子导向系统肽及其用途

Publications (2)

Publication Number Publication Date
CN111278847A CN111278847A (zh) 2020-06-12
CN111278847B true CN111278847B (zh) 2024-04-19

Family

ID=65002631

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880055674.8A Active CN111278847B (zh) 2017-07-10 2018-07-10 分子导向系统肽及其用途
CN202410388889.9A Pending CN118221770A (zh) 2017-07-10 2018-07-10 分子导向系统肽及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410388889.9A Pending CN118221770A (zh) 2017-07-10 2018-07-10 分子导向系统肽及其用途

Country Status (6)

Country Link
US (3) US11965004B2 (https=)
EP (1) EP3652196A4 (https=)
JP (3) JP7289029B2 (https=)
CN (2) CN111278847B (https=)
AU (3) AU2018301804B2 (https=)
WO (1) WO2019014190A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11965004B2 (en) 2017-07-10 2024-04-23 Sri International Molecular guide system peptides and uses thereof
CN118240025A (zh) 2017-07-10 2024-06-25 斯坦福国际研究院 用于治疗癌症的肽皂草素缀合物
US20220380764A1 (en) * 2019-10-01 2022-12-01 Sri International Molecular guide system peptides and uses thereof
US20230364261A1 (en) * 2020-09-21 2023-11-16 Sri International Targeted antigen delivery system and uses thereof
WO2025106488A1 (en) * 2023-11-13 2025-05-22 Sri International Lung fibroblast-specific molecular guidance system peptides and uses thereof
CN118440159A (zh) * 2024-04-28 2024-08-06 中国人民解放军海军军医大学第二附属医院 一种预防或治疗心肌缺血再灌注损伤的多肽及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004003170A2 (en) * 2002-06-28 2004-01-08 The Johns Hopkins University Agents capable of inhibiting ras and uses thereof
CN101724073A (zh) * 2010-01-19 2010-06-09 成都军区昆明总医院 一种广谱抗ras基因表达蛋白的单克隆抗体及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
JP2006521088A (ja) * 2002-11-15 2006-09-21 メディカル リサーチ カウンシル 抗活性化ｒａｓ抗体
CA2524124C (en) 2003-04-30 2014-03-25 Uwe Zangemeister-Wittke Methods for treating cancer using an immunotoxin
WO2005081898A2 (en) 2004-02-20 2005-09-09 The Trustees Of The University Of Pennsylvania Binding peptidomimetics and uses of the same
EP1867661A1 (en) * 2006-06-12 2007-12-19 Diatos Compositions and methods for delivering anti-activated ras antibodies into cells
US20090110662A1 (en) * 2007-04-30 2009-04-30 Intezyne Technologies, Inc. Modification of biological targeting groups for the treatment of cancer
WO2009089186A2 (en) 2008-01-05 2009-07-16 Sloan-Kettering Institute For Cancer Research Peptide-conjugated oligonucleotide therapeutic and method of making and using same
EP2352522A4 (en) * 2008-11-06 2014-03-05 Univ Washington BISPECIFIC AUXILIARIES FOR INTRA-CELLULAR RELEASE
US8241623B1 (en) * 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US8481678B2 (en) * 2009-03-30 2013-07-09 E I Du Pont De Nemours And Company Peptide-based tooth whitening reagents
US8524220B1 (en) * 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8362207B2 (en) * 2010-04-16 2013-01-29 Wake Forest University Health Sciences Multi-level specific targeting of cancer cells with IL-13
WO2012040513A1 (en) * 2010-09-22 2012-03-29 The Board Of Regents Of The University Of Texas System Compositions and methods for the delivery of beta lapachone
CA2816584A1 (en) * 2010-11-01 2012-05-10 Peptimed, Inc. Compositions of a peptide-based system for cell-specific targeting
US8515001B2 (en) * 2010-12-24 2013-08-20 Lg Display Co., Ltd. Shift register
EP2476441A1 (en) 2011-01-13 2012-07-18 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells
US20120283410A1 (en) * 2011-03-14 2012-11-08 Intezyne Technologies, Incorporated Attachment of biological targeting groups using metal free click chemistry
US9062312B2 (en) * 2011-06-21 2015-06-23 Danisco Us Inc. Fusion peptides comprising multi-functional peptidic solubility tags for efficient production, processing and surface applications
US9572898B2 (en) * 2013-09-09 2017-02-21 Seton Hall University Functionalized fluorine containing phthalocyanine molecules
GB201318954D0 (en) * 2013-10-28 2013-12-11 Cupid Peptide Company Ltd Cell transport
PT3137605T (pt) 2014-05-01 2020-12-18 Ionis Pharmaceuticals Inc Composições e métodos para modulação da expressão de angiopoietina de tipo 3
WO2016022597A1 (en) 2014-08-04 2016-02-11 Case Western Reserve University Targeting peptides and methods of use
EP3226840B1 (en) 2014-12-17 2020-07-29 SRI International Antigen delivery system
US20180157388A1 (en) 2016-12-02 2018-06-07 Google Inc. Emotion expression in virtual environment
CA3047491A1 (en) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
CN118240025A (zh) 2017-07-10 2024-06-25 斯坦福国际研究院 用于治疗癌症的肽皂草素缀合物
US11965004B2 (en) 2017-07-10 2024-04-23 Sri International Molecular guide system peptides and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004003170A2 (en) * 2002-06-28 2004-01-08 The Johns Hopkins University Agents capable of inhibiting ras and uses thereof
CN101724073A (zh) * 2010-01-19 2010-06-09 成都军区昆明总医院 一种广谱抗ras基因表达蛋白的单克隆抗体及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A cancer specific cell-penetrating peptide,BR2,for the efficient delivery of an scFv into cancer cells;Lim K J,Sung B H,Shin J R,et al.;《PloS one》;20130611;第8卷(第6期);文章摘要、第10页左栏第二段 *
Lim K J,Sung B H,Shin J R,et al..A cancer specific cell-penetrating peptide,BR2,for the efficient delivery of an scFv into cancer cells.《PloS one》.2013,第8卷(第6期),第e66084-e66094页. *

Also Published As

Publication number Publication date
JP2025081638A (ja) 2025-05-27
JP7289029B2 (ja) 2023-06-09
EP3652196A4 (en) 2021-08-18
AU2024227641A1 (en) 2024-11-14
US20240209041A1 (en) 2024-06-27
EP3652196A1 (en) 2020-05-20
JP7642700B2 (ja) 2025-03-10
JP2023085493A (ja) 2023-06-20
WO2019014190A1 (en) 2019-01-17
US12441774B2 (en) 2025-10-14
US20260015395A1 (en) 2026-01-15
AU2018301804A1 (en) 2020-01-30
US11965004B2 (en) 2024-04-23
CN111278847A (zh) 2020-06-12
CN118221770A (zh) 2024-06-21
JP2020535110A (ja) 2020-12-03
AU2018301804B2 (en) 2024-07-25
US20220227823A1 (en) 2022-07-21
AU2026201731A1 (en) 2026-03-26
AU2024227641B2 (en) 2025-12-18

Similar Documents

Publication Publication Date Title
CN111278847B (zh) 分子导向系统肽及其用途
JP2019104738A (ja) 細胞内在化を誘導するためのｃｄ２０結合免疫毒素及びそれを用いる方法
US12576157B2 (en) Peptide saporin conjugate for the treatment of cancer
AU2020357455B2 (en) Molecular guide system peptides and uses thereof
JP2011200233A5 (https=)
JP5864556B2 (ja) インスリン様成長因子１受容体結合ペプチド
TW201809013A (zh) 用於藥物遞送之抗體融合蛋白
JP4858803B2 (ja) 抗ｍｒｄ（微少残存白血病）薬
EP4229090A1 (en) Anti-gpc4 single domain antibodies
US20210138075A1 (en) Cell internalizing compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant